Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials. (PubMed, J Allergy Clin Immunol) - Oct 21, 2026 - "High-frequency dupilumab and STCs are among the most effective therapies across patient-important and inflammatory outcomes. Histologic improvements do not guarantee patient-important outcome improvement. FED benefits are modest and low certainty, and traded off by burdens."
Journal • Retrospective data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation
|
|
Aikaterini Anagnostou; Alexandro W L Chu; Anita Chandra-Puri; Daniel Rayner; Derek K Chu; Ellen M McCabe; Henry Bernstein; Hugh A Sampson; Isabella Silang; Jay Lieberman; Jennifer Gerdts; Jonathan S Tam; Julie Wang; Kelly Cleary; Kirsi M Järvinen; Lynda Mitchell; Marcus Shaker; Maria Crain; Marion Groetch; Mary Sherlock; Matthew A Rank; Matthew Greenhawt; Melanie Carver; Michael M Cyr; Nazmul Islam; Patricia C Fulkerson; Phillippe Bégin; R Sharon Chinthrajah; Sally Joo Bailey; Scott H Sicherer; Shahzad Mustafa; Ted Xenodemetropoulos; Vanessa Wong; Yetiani Roldán; Zachary Brunet
|